This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de la Iglesia, P.
Right arrow Articles by de Oña, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de la Iglesia, P.
Right arrow Articles by de Oña, M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 1998, p. 2389-2391, Vol. 36, No. 8
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Rapid Screening Tests for Determining In Vitro Susceptibility of Herpes Simplex Virus Clinical Isolates

Pedro de la Iglesia,* Santiago Melón, Beatriz López, Mercedes Rodriguez, Maria I. Blanco, Purificación Mellado, and Maria de Oña

Laboratorio de Virología, Servicio de Microbiologia, Hospital Covadonga, 33006 Oviedo, Asturias, Spain

Received 3 November 1997/Returned for modification 26 March 1998/Accepted 4 May 1998

The susceptibility of human herpes simplex virus (HSV) to acyclovir (ACV) was determined with the use of a single dose of the drug (1 and 2 µg of ACV per ml for HSV-1 and HSV-2, respectively) in two rapid assays: a rapid cytopathic effect inhibitory assay (Rapid CIA) and a rapid dye uptake assay (Rapid DUA). These tests allow the simultaneous determination of virus titer and susceptibility to ACV at a determined viral concentration (100 50% tissue culture infective doses and 100 50% dye uptake units). These tests were compared with a conventional susceptibility assay (dye uptake assay) and showed similar results. Indeterminate results with the Rapid CIA appeared in 3 of 30 samples. With the use of both Rapid CIA and Rapid DUA, we were able to determine the susceptibility of 100% of the isolates. The rapid tests, unlike conventional assays, are able to provide susceptibility results within 3 days after the virus has been isolated from a clinical specimen and could thus play a direct role in therapeutic decisions.

* Corresponding author. Mailing address: Laboratorio de Virología, Servicio de Microbiología, Hospital Covadonga, Celestino Villamil, s. n., 33006 Oviedo, Asturias, Spain. Phone: 34-8-5108720. Fax: 34-8-5108015. E-mail: virologia{at}hcq.es.

Journal of Clinical Microbiology, August 1998, p. 2389-2391, Vol. 36, No. 8
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Chutkowski, C., Olson, B., McDonough, A., Mahoney, J., McSharry, J. J. (2002). Use of a Single Monoclonal Antibody To Determine the Susceptibilities of Herpes Simplex Virus Type 1 and Type 2 Clinical Isolates to Acyclovir. CVI 9: 1379-1381 [Abstract] [Full Text]  
  • Sahli, R., Andrei, G., Estrade, C., Snoeck, R., Meylan, P. R. A. (2000). A Rapid Phenotypic Assay for Detection of Acyclovir-Resistant Varicella-Zoster Virus with Mutations in the Thymidine Kinase Open Reading Frame. Antimicrob. Agents Chemother. 44: 873-878 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»